(Q24644555)

English

COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features

scientific article

COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): relevance for motor and non-motor features

In more languages

Statements

scholarly article

0 references

COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features (English)

0 references

Parkinson's disease

1 reference

based on heuristic

inferred from title

3

0 references

Angelo Antonini

1

object named as

Angelo Antonini

0 references

8

object named as

Aldo Quattrone

0 references

Leonardo Lopiano

5

object named as

Leonardo Lopiano

0 references

7

object named as

Mario Zappia

0 references

author name string

Giovanni Abbruzzese

2

0 references

Ubaldo Bonuccelli

4

0 references

Marco Onofrj

6

0 references

language of work or name

0 references

publication date

February 2008

0 references

Neuropsychiatric Disease and Treatment

0 references

4

0 references

1

0 references

1-9

0 references

Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

7 April 2017

Rasagiline: a review of its use in the management of Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

7 April 2017

Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

7 April 2017

Treatment interventions for Parkinson's disease: an evidence based assessment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

7 April 2017

Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

7 April 2017

When should levodopa therapy be initiated in patients with Parkinson's disease?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

27 September 2017

Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

27 September 2017

Tolcapone in the management of Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

27 September 2017

Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

27 September 2017

The neuropsychiatry of Parkinson's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

27 September 2017

Alternatives to levodopa in the initial treatment of early Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

27 September 2017

Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

27 September 2017

A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

27 September 2017

Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

27 September 2017

Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

27 September 2017

An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

27 September 2017

COMT inhibitors and liver toxicity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

27 September 2017

Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

27 September 2017

Tolcapone and hepatotoxic effects. Tasmar Advisory Panel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

27 September 2017

The rise and fall of tolcapone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

27 September 2017

Parkinson's disease. Second of two parts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

27 September 2017

Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

27 September 2017

The response to levodopa in Parkinson's disease: imposing pharmacological law and order

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

27 September 2017

L-dihydroxyphenylalanine and its decarboxylase: new ideas on their neuroregulatory roles.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

27 September 2017

Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

30 May 2018

Mood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion: preliminary findings.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

30 May 2018

The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

28 November 2018

Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

28 November 2018

Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

28 November 2018

International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

28 November 2018

Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

28 November 2018

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

28 November 2018

Levodopa challenge neuroimaging of levodopa-related mood fluctuations in Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

28 November 2018

Motor complications in dopa treatment of parkinson disease: clinical description and evaluation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

28 November 2018

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

28 November 2018

Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

28 November 2018

Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

28 November 2018

18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

28 November 2018

Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

28 November 2018

Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

28 November 2018

Switch-over from tolcapone to entacapone in severe Parkinson's disease patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

28 November 2018

Gait analysis in advanced Parkinson's disease--effect of levodopa and tolcapone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

28 November 2018

Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicenter study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

28 November 2018

Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

28 November 2018

Mood response to levodopa infusion in early Parkinson's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

28 November 2018

Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515921

28 November 2018

Loss of long-duration response to levodopa over time in PD: implications for wearing-off

1 reference

https://pubmed.ncbi.nlm.nih.gov/18728767

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacodynamics of the long-duration response to levodopa in PD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18728767

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/18728767

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nonmotor fluctuations in Parkinson's disease: frequent and disabling

1 reference

https://pubmed.ncbi.nlm.nih.gov/18728767

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Entacapone to tolcapone switch: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/18728767

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/18728767

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The subacute levodopa test for evaluating long-duration response in parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/18728767

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of brief levodopa holidays on the short-duration response to levodopa: evidence for tolerance to the antiparkinsonian effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/18728767

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The spectrum of levodopa-related fluctuations in Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/18728767

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/18728767

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacodynamics of levodopa in Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/18728767

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/18728767

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/18728767

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2147/NDT.S2404

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24644555&oldid=1578514890"